Checked.be
Active
BE 0719.798.495Private limited company
Curans
Leopold Decouxlaan 192 ·3012 Leuven, Belgium· 7 yrs active
Sector: General medical practice
(86210)
Conclusion
Curans has been active since 2019 and the Belgian State Gazette contains no insolvency or warning signals. The 2026 annual accounts show equity of €100 and a net result of €33k. Equity remains stable across the filed fiscal years (±0% per year). Its solvency ranks better than 11% of 54 sector peers (fiscal year 2026). The computed 12-month bankruptcy probability is 0.1% (very low).
Based on the State Gazette, CBE and 6 annual accounts.
Key figures
| Equity | €100 |
| Net result | €33k |
| Better than sector | 11% |
| Active | 7 yrs |
Financial profile
62
/ 100
Strong profile, led by profitability.
All 5 axes are computed from data Checked has read.
Health
45
Profitability
100
Solvency
7
Growth
58
Stability
100
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
More than 3 years active
Founded in 2019, past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
45
/ 100
Fair
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
No credit
negative equity or figures too weak
Score history
75
2021
61
2022
45
2023
45
2024
53
2025
45
2026
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 0.83 (< 1.0)
-10
Leverage
Debt/equity 619.60 (> 3.0)
-10
Profitability
ROE 32529% (≥ 10%)
+10
Interest coverage
Interest coverage 808.5× (≥ 3×)
+8
Profit trend
Net profit down YoY
-3
Computed by Checked from the NBB filing for FY 2026. Indicative, not credit advice.
Financial overview
Annual accounts filed on 04-06-2026 with the NBB · fiscal year 2026 · micro schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
stable
Equity: stable across 6 fiscal years (±0%/year).
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2026 · NACE 86, Human health activities · compared within the same schema type (micro schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 0.2% | 44.9% | |
| Net result | €33k | €55k | |
| Equity | €100 | €74k | |
| Gross operating margin | €44k | €69k | |
| Total assets | €62k | €316k |
€149k
-
21-26
€44k
-8.1%
21-26
€33k
-7.3%
21-26
€35k
-8.0%
21-26
€62k
+11.9%
21-26
€100
0.0%
21-26
€-11k
+6.8%
21-26
€9k
-8.5%
21-26
€33k
-7.3%
21-26
€62k
+11.9%
21-26
€62k
+11.9%
21-26
0.83
+4.5%
21-26
0.83
+4.5%
21-26
0.2%
-10.6%
21-26
619.60
+11.9%
21-26
32529.0%
-7.3%
21-26
52.4%
-17.1%
21-26
39.1%
-
21-26
50.9%
-
21-26
808.54
-10.7%
21-26
Figures by fiscal year and ratios
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Deposit | micro schema | micro schema | micro schema | micro schema | micro schema |
| Revenue | - | - | - | - | €149k |
| EBITDA | €44k | €48k | €29k | €53k | €76k |
| Net profit | €33k | €35k | €18k | €41k | €58k |
| Cash flow | €35k | €38k | €24k | €43k | €61k |
| Staff costs | - | - | - | - | - |
| Income taxes | €9k | €10k | €5k | €10k | €15k |
| Dividends | €33k | €35k | €18k | €41k | €78k |
| Total assets | €62k | €55k | €56k | €53k | €63k |
| Equity | €100 | €100 | €100 | €100 | €100 |
| Debt | €62k | €55k | €56k | €53k | €63k |
| of which ≤ 1y | €62k | €55k | €56k | €53k | €63k |
| of which > 1y | - | - | - | - | - |
| Working capital | €-11k | €-12k | €-14k | €-20k | €-5k |
| Employees (FTE) | - | - | - | - | - |
Ratios (computed)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Current ratio | 0.83 | 0.79 | 0.75 | 0.63 | 0.92 |
| Quick ratio | 0.83 | 0.79 | 0.75 | 0.63 | 0.92 |
| Working capital ratio | -17.5% | -21.0% | -25.4% | -37.2% | -8.0% |
| Solvency | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% |
| Debt / equity | 619.60 | 553.75 | 562.93 | 527.87 | 627.53 |
| Long-term debt ratio | - | - | - | - | - |
| Interest coverage | 808.54 | 904.95 | 603.59 | 1108.39 | 1695.03 |
| Gross margin | - | - | - | - | 51.4% |
| Net margin | - | - | - | - | 39.1% |
| ROA | 52.4% | 63.3% | 32.4% | 76.7% | 93.0% |
| ROE | 32529.0% | 35093.6% | 18278.6% | 40577.8% | 58437.0% |
| EBITDA margin | - | - | - | - | 50.9% |
| Days sales outstanding | - | - | - | - | 19d |
| Days payable outstanding | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days inventory (DSI) | - | - | - | - | - |
Balance-sheet composition 2026
Full annual accounts (20 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Balance sheet, Assets | ||||||
| TOTAL ASSETS | 20/58 | €62k | €55k | €56k | €53k | €63k |
| Fixed assets | 21/28 | €11k | €12k | €14k | €20k | €5k |
| Tangible fixed assets | 22/27 | €11k | €12k | €14k | €20k | €5k |
| Current assets | 29/58 | €51k | €44k | €42k | €33k | €58k |
| Amounts receivable within one year | 40/41 | €20k | - | €2k | - | €8k |
| Cash & bank | 54/58 | €30k | €42k | €38k | €20k | €47k |
| Balance sheet, Equity & liabilities | ||||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €62k | €55k | €56k | €53k | €63k |
| Equity | 10/15 | €100 | €100 | €100 | €100 | €100 |
| Contributions / capital | 10/11 | €100 | €100 | €100 | €100 | €100 |
| Amounts payable | 17/49 | €62k | €55k | €56k | €53k | €63k |
| Amounts payable within one year | 42/48 | €62k | €55k | €56k | €53k | €63k |
| Trade debts payable within one year | 44 | €521 | - | €677 | - | - |
| Income statement | ||||||
| Turnover | 70 | - | - | - | - | €149k |
| Gross operating margin | 9900 | €44k | €48k | €30k | €54k | €77k |
| Operating result | 9901 | €41k | €45k | €24k | €51k | €73k |
| Financial charges | 65 | €54 | €53 | €48 | €48 | €45 |
| Result before taxes | 9903 | €41k | €45k | €24k | €51k | €73k |
| Income taxes | 67/77 | €9k | €10k | €5k | €10k | €15k |
| Net result for the period | 9904 | €33k | €35k | €18k | €41k | €58k |
| Result to be appropriated | 9905 | €33k | €35k | €18k | €41k | €58k |
Legal Structure
| NACE primary | General medical practice(86210) |
| Legal form | Private limited company(610) |
| Incorporation | 04-02-2019 |
| Status | Active |
| Postal code | 3012 |
Establishment units
Leopold Decouxlaan 192, 3012 Leuven
since 20192.285.127.483
Real-estate footprint
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 24126D0294/00S002 | Flanders | 554 m² | 1 · 148 m² | 10.2 m · 2 fl. |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
Next filing, fiscal year 2027, expected by
2026
04-06
NBB filing
Annual accounts filed
fiscal year 2026 · micro schema
2025
30-09
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2024
30-10
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2023
30-10
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2022
28-10
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
31-03
Financial
Highest result since 2021net €58k ▲232%
Operating result €73k, net result €58k, both a record.
2021
29-10
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
2020
03-10
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
2019
19-09
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Activities
General medical practice86210Rental and leasing activities77225Rental and leasing activities77330Human health activities86909Nutrition and dietetics services86995
Names & trade names
| Legal nameNL | Curans |
Similar companies
DR GREGOIRE VIOLAINE
BE 0628.986.404 · Genappe
Dr. Alexander De Loof
BE 0687.740.688 · Brugge
Alexander De Keersmaeker, huisarts
BE 0733.863.792 · Beveren-Kruibeke-Zwijndrecht
FERYASU
BE 0734.635.438 · Bertem
Dokter Emma Verfaillie
BE 0753.439.283 · Leuven